Business

TG Therapeutics Announces Pivotal Data from the UNITY-CLL and UNITY-NHL Clinical Trials Presented at the 62nd American Society of Hematology Annual Meeting

UNITY-CLL: U2 significantly improved progression-free survival over obinutuzumab plus chlorambucil (HR=0.54,

articleTg Therapeutics, Inc.December 7, 20205/company/tg-therapeutics-inc/news/tg-therapeutics-announces-pivotal-data-from-the-unity-cll-and-unity-nhl-clinical

TG Therapeutics Announces Pivotal Data from the UNITY-CLL and UNITY-NHL Clinical Trials Presented at the 62nd American Society of Hematology Annual Meeting

About this update from Tg Therapeutics, Inc.

[{"type":"text","content":"UNITY-CLL: U2 significantly improved progression-free survival over obinutuzumab plus chlorambucil (HR=0.54, p","length":180,"tagName":"div"}]

More updates from Tg Therapeutics, Inc.